恶性外周神经鞘瘤治疗与生存的全国队列研究
该研究基于荷兰癌症登记处和荷兰病理数据库,纳入629例局部成人恶性外周神经鞘瘤(MPNST),其中腹膜后35例(5.5%)。分析显示可切除性是最重要的生存预测因素,R1与R0切除生存相似,放化疗与生存无关。
要点
- 可切除性是MPNST最重要的生存预测因素。
- 非腹膜后MPNST中,年龄60+、NF1、大小>5cm和深部肿瘤与更差生存独立相关。
- 腹膜后MPNST中,男性和年龄60+与更差生存独立相关。
核心结论
- 局部MPNST可通过患者和肿瘤特异性特征进行生存风险分层。
- 可切除性是MPNST最重要的生存预测因素。
- 腹膜后和非腹膜后MPNST中R1与R0切除生存无差异。
- 放化疗的附加价值不明确。
研究设计与样本
- 全国队列研究,数据来自荷兰癌症登记处和荷兰病理数据库。
- 纳入所有原发性MPNST,排除年龄≤18岁儿科病例和同时性转移。
- 共分析629例局部成人MPNST,其中腹膜后35例(5.5%)。
- 分别对腹膜后和非腹膜后MPNST建立Cox比例风险模型。
主要发现
- 手术切除患者占88.1%,放疗和化疗分别占44.2%和6.7%。
- 腹膜后病例中放疗显著较少、化疗较多。
- 非腹膜后MPNST中,年龄60+、NF1、大小>5cm和深部肿瘤与更差生存独立相关。
- 腹膜后MPNST中,男性和年龄60+与更差生存独立相关。
- R1与R0切除生存相似,R2切除与更差结局相关;放化疗与生存无关。
临床怎么用
- 对局部MPNST应基于患者和肿瘤特征进行生存风险分层。
- 治疗决策应优先考虑可切除性。
- R1切除后无需因切缘状态而常规强化治疗,因R1与R0生存相似。
- 放化疗的常规使用缺乏生存获益证据,需个体化权衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite curative intents of treatment in localized malignant peripheral nerve sheath tumours (MPNSTs), prognosis remains poor. This study investigated survival and prognostic factors for overall survival in non-retroperitoneal and retroperitoneal MPNSTs in the Netherlands. METHODS: Data were obtained from the Netherlands Cancer Registry and the Dutch Pathology Database. All primary MPNSTs were collected. Paediatric cases (age ≤18 years) and synchronous metastases were excluded from analyses. Separate Cox proportional hazard models were made for retroperitoneal and non-retroperitoneal MPNSTs. RESULTS: A total of 629 localized adult MPNSTs (35 retroperitoneal cases, 5.5%) were included for analysis. In surgically resected patients (88.1%), radiotherapy and chemotherapy were administered in 44.2% and 6.7%, respectively. In retroperitoneal cases, significantly less radiotherapy and more chemotherapy were applied. In non-retroperitoneal MPNSTs, older age (60+), presence of NF1, size >5 cm, and deep-seated tumours were independently associated with worse survival. In retroperitoneal MPNSTs, male sex and age of 60+ years were independently associated with worse survival. Survival of R1 and that of R0 resections were similar for any location, whereas R2 resections were associated with worse outcomes. Radiotherapy and chemotherapy administrations were not associated with survival. CONCLUSION: In localized MPNSTs, risk stratification for survival can be done using several patient- and tumour-specific characteristics. Resectability is the most important predictor for survival in MPNSTs. No difference is present between R1 and R0 resections in both retroperitoneal and non-retroperitoneal MPNSTs. The added value of radiotherapy and chemotherapy is unclear.
引用
- Martin E, Coert JH, Flucke UE, et al. A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours. Eur J Cancer. 2019. PMID: 31760312. doi:10.1016/j.ejca.2019.10.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。